Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study

{ 'indexed': {'date-parts': [[2024, 4, 15]], 'date-time': '2024-04-15T23:16:47Z', 'timestamp': 1713223007948}, 'reference-count': 95, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2021, 10, 1]], 'date-time': '2021-10-01T00:00:00Z', 'timestamp': 1633046400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2021, 10, 1]], 'date-time': '2021-10-01T00:00:00Z', 'timestamp': 1633046400000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-017'}, { 'start': { 'date-parts': [[2021, 10, 1]], 'date-time': '2021-10-01T00:00:00Z', 'timestamp': 1633046400000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-037'}, { 'start': { 'date-parts': [[2021, 10, 1]], 'date-time': '2021-10-01T00:00:00Z', 'timestamp': 1633046400000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-012'}, { 'start': { 'date-parts': [[2021, 10, 1]], 'date-time': '2021-10-01T00:00:00Z', 'timestamp': 1633046400000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-029'}, { 'start': { 'date-parts': [[2021, 10, 1]], 'date-time': '2021-10-01T00:00:00Z', 'timestamp': 1633046400000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-004'}], 'content-domain': {'domain': ['elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 10]]}, 'DOI': '10.1016/j.intimp.2021.108004', 'type': 'journal-article', 'created': {'date-parts': [[2021, 7, 23]], 'date-time': '2021-07-23T12:23:55Z', 'timestamp': 1627043035000}, 'page': '108004', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 10, 'title': 'Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A ' 'preclinical tolerance study', 'prefix': '10.1016', 'volume': '99', 'author': [ {'given': 'Suzan', 'family': 'M. Mansour', 'sequence': 'first', 'affiliation': []}, {'given': 'Rehab', 'family': 'N. Shamma', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kawkab', 'family': 'A. Ahmed', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nirmeen', 'family': 'A. Sabry', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gamal', 'family': 'Esmat', 'sequence': 'additional', 'affiliation': []}, {'given': 'Azza', 'family': 'A. Mahmoud', 'sequence': 'additional', 'affiliation': []}, {'given': 'Amr', 'family': 'Maged', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.intimp.2021.108004_b0005', 'unstructured': 'Centers for Disease Control and Prevention. Coronavirus (COVID-19): Get ' 'the Facts About Coronavirus. 2020 [cited 2020 6/9/2020]; Available from: ' 'https://www.cdc.gov/coronavirus/2019-ncov/index.html.'}, { 'issue': '8', 'key': '10.1016/j.intimp.2021.108004_b0010', 'first-page': '4539', 'article-title': 'Efficacy of chloroquine and hydroxychloroquine in the treatment of ' 'COVID-19', 'volume': '24', 'author': 'Meo', 'year': '2020', 'journal-title': 'Eur. Rev. Med. Pharmacol. Sci.'}, { 'key': '10.1016/j.intimp.2021.108004_b0015', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.nmni.2020.100680', 'article-title': 'Review on the global epidemiological situation and the efficacy of ' 'chloroquine and hydroxychloroquine for the treatment of COVID-19', 'volume': '35', 'author': 'Saqrane', 'year': '2020', 'journal-title': 'New Microbes New Infect.'}, { 'issue': '7', 'key': '10.1016/j.intimp.2021.108004_b0020', 'doi-asserted-by': 'crossref', 'first-page': '450', 'DOI': '10.1136/emermed-2020-210221.2', 'article-title': 'BET 1: Lopinavir-ritonavir and COVID-19', 'volume': '37', 'author': 'Dolan', 'year': '2020', 'journal-title': 'Emerg. Med. J.'}, { 'issue': '7', 'key': '10.1016/j.intimp.2021.108004_b0025', 'doi-asserted-by': 'crossref', 'DOI': '10.3390/jcm9072050', 'article-title': 'Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of ' 'Current Evidence, Guideline Recommendations, and Perspectives', 'volume': '9', 'author': 'Meini', 'year': '2020', 'journal-title': 'J. Clin. Med.'}, { 'issue': '2', 'key': '10.1016/j.intimp.2021.108004_b0030', 'doi-asserted-by': 'crossref', 'first-page': '45', 'DOI': '10.1016/S2055-6640(20)30016-9', 'article-title': 'A review of the safety of favipiravir - a potential treatment in the ' 'COVID-19 pandemic?', 'volume': '6', 'author': 'Pilkington', 'year': '2020', 'journal-title': 'J. Virus Erad.'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.108004_b0035', 'doi-asserted-by': 'crossref', 'first-page': '702', 'DOI': '10.1186/s13063-020-04616-4', 'volume': '21', 'author': 'Akram', 'year': '2020', 'journal-title': 'Trials.'}, { 'key': '10.1016/j.intimp.2021.108004_b0040', 'article-title': 'The impact of sofosbuvir/daclatasvir or ribavirin in patients with ' 'severe COVID-19', 'volume': '19', 'author': 'Eslami', 'year': '2020', 'journal-title': 'J. Antimicrob. Chemother.'}, { 'key': '10.1016/j.intimp.2021.108004_b0045', 'article-title': 'Evaluation of the efficacy of sofosbuvir plus daclatasvir in ' 'combination with ribavirin for hospitalized COVID-19 patients with ' 'moderate disease compared with standard care: a single-centre, ' 'randomized controlled trial', 'volume': '19', 'author': 'Abbaspour Kasgari', 'year': '2020', 'journal-title': 'J. Antimicrob. Chemother.'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.108004_b0050', 'doi-asserted-by': 'crossref', 'first-page': '23', 'DOI': '10.1186/s12941-020-00368-w', 'article-title': 'Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19', 'volume': '19', 'author': 'Sharun', 'year': '2020', 'journal-title': 'Ann Clin Microbiol Antimicrob.'}, { 'issue': '9', 'key': '10.1016/j.intimp.2021.108004_b0055', 'doi-asserted-by': 'crossref', 'first-page': '593', 'DOI': '10.1038/s41429-020-0336-z', 'article-title': 'Ivermectin: a systematic review from antiviral effects to COVID-19 ' 'complementary regimen', 'volume': '73', 'author': 'Heidary', 'year': '2020', 'journal-title': 'J. Antibiot. (Tokyo)'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.108004_b0060', 'doi-asserted-by': 'crossref', 'first-page': '42', 'DOI': '10.1208/s12248-007-9000-9', 'article-title': 'The pharmacokinetics and interactions of ivermectin in humans–a ' 'mini-review', 'volume': '10', 'author': 'Gonzalez Canga', 'year': '2008', 'journal-title': 'AAPS J.'}, { 'key': '10.1016/j.intimp.2021.108004_b0065', 'doi-asserted-by': 'crossref', 'DOI': '10.1002/14651858.CD012994', 'article-title': 'Ivermectin and permethrin for treating scabies', 'author': 'Rosumeck', 'year': '2018', 'journal-title': 'Cochrane Database Syst. Rev.'}, { 'issue': '5', 'key': '10.1016/j.intimp.2021.108004_b0070', 'doi-asserted-by': 'crossref', 'first-page': '495', 'DOI': '10.1038/ja.2017.11', 'article-title': "Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise " 'and exceed expectations', 'volume': '70', 'author': 'Crump', 'year': '2017', 'journal-title': 'J. Antibiot. (Tokyo)'}, { 'issue': '2', 'key': '10.1016/j.intimp.2021.108004_b0075', 'first-page': '317', 'article-title': 'The multitargeted drug ivermectin: from an antiparasitic agent to a ' 'repositioned cancer drug', 'volume': '8', 'author': 'Juarez', 'year': '2018', 'journal-title': 'Am J Cancer Res.'}, { 'issue': '13', 'key': '10.1016/j.intimp.2021.108004_b0080', 'doi-asserted-by': 'crossref', 'first-page': '1549', 'DOI': '10.1016/j.bmcl.2019.04.045', 'article-title': 'Doxycycline, salinomycin, monensin and ivermectin repositioned as ' 'cancer drugs', 'volume': '29', 'author': 'Markowska', 'year': '2019', 'journal-title': 'Bioorg. Med. Chem. Lett.'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.108004_b0085', 'doi-asserted-by': 'crossref', 'first-page': '38', 'DOI': '10.1016/j.diagmicrobio.2019.03.012', 'article-title': 'Lack of efficacy of ivermectin for prevention of a lethal Zika virus ' 'infection in a murine system', 'volume': '95', 'author': 'Ketkar', 'year': '2019', 'journal-title': 'Diagn. Microbiol. Infect. Dis.'}, { 'issue': '3', 'key': '10.1016/j.intimp.2021.108004_b0090', 'doi-asserted-by': 'crossref', 'first-page': '851', 'DOI': '10.1042/BJ20120150', 'article-title': 'Ivermectin is a specific inhibitor of importin alpha/beta-mediated ' 'nuclear import able to inhibit replication of HIV-1 and dengue virus', 'volume': '443', 'author': 'Wagstaff', 'year': '2012', 'journal-title': 'Biochem. J.'}, { 'key': '10.1016/j.intimp.2021.108004_b0095', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 ' 'in vitro', 'volume': '178', 'author': 'Caly', 'year': '2020', 'journal-title': 'Antiviral Res.'}, { 'key': '10.1016/j.intimp.2021.108004_b0100', 'first-page': '1', 'article-title': 'Binding mechanism and structural insights into the identified protein ' 'target of COVID-19 and importin-alpha with in-vitro effective drug ' 'ivermectin', 'volume': '28', 'author': 'Sen Gupta', 'year': '2020', 'journal-title': 'J. Biomol. Struct. Dyn.'}, { 'issue': '5', 'key': '10.1016/j.intimp.2021.108004_b0105', 'doi-asserted-by': 'crossref', 'first-page': '1037', 'DOI': '10.1021/acsptsci.0c00140', 'article-title': 'Ivermectin, Famotidine, and Doxycycline: A Suggested Combinatorial ' 'Therapeutic for the Treatment of COVID-19', 'volume': '3', 'author': 'Sen Gupta', 'year': '2020', 'journal-title': 'ACS Pharmacol Transl Sci.'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.108004_b0110', 'doi-asserted-by': 'crossref', 'first-page': '469', 'DOI': '10.1080/13102818.2020.1775118', 'article-title': 'Ivermectin as a potential COVID-19 treatment from the pharmacokinetic ' 'point of view: antiviral levels are not likely attainable with known ' 'dosing regimens', 'volume': '34', 'author': 'Momekov', 'year': '2020', 'journal-title': 'Biotechnol. Biotechnol. Equip.'}, { 'issue': '6', 'key': '10.1016/j.intimp.2021.108004_b0115', 'doi-asserted-by': 'crossref', 'first-page': '1156', 'DOI': '10.4269/ajtmh.20-0271', 'article-title': 'Ivermectin and COVID-19: Keeping Rigor in Times of Urgency', 'volume': '102', 'author': 'Chaccour', 'year': '2020', 'journal-title': 'Am. J. Trop. Med. Hyg.'}, { 'issue': '10', 'key': '10.1016/j.intimp.2021.108004_b0120', 'doi-asserted-by': 'crossref', 'first-page': '1122', 'DOI': '10.1177/009127002237994', 'article-title': 'Safety, tolerability, and pharmacokinetics of escalating high doses of ' 'ivermectin in healthy adult subjects', 'volume': '42', 'author': 'Guzzo', 'year': '2002', 'journal-title': 'J. Clin. Pharmacol.'}, { 'key': '10.1016/j.intimp.2021.108004_b0125', 'unstructured': 'INCHEM. Ivermectin. 2020 [cited 2020 7/9/2020]; Available from: ' 'http://www.inchem.org/documents/pims/pharm/ivermect.htm.'}, { 'key': '10.1016/j.intimp.2021.108004_b0130', 'unstructured': 'Merck Sharp Dohme. Product information for AusPAR Stromectol Ivermectin. ' '2013.'}, { 'issue': '4', 'key': '10.1016/j.intimp.2021.108004_b0135', 'doi-asserted-by': 'crossref', 'first-page': '775', 'DOI': '10.1002/cpt.1909', 'article-title': 'Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based ' 'on Plasma and Target Site Concentrations Derived from their Established ' 'Human Pharmacokinetics', 'volume': '108', 'author': 'Arshad', 'year': '2020', 'journal-title': 'Clin. Pharmacol. Ther.'}, { 'key': '10.1016/j.intimp.2021.108004_b0140', 'doi-asserted-by': 'crossref', 'DOI': '10.1002/cpt.1889', 'article-title': 'The Approved Dose of Ivermectin Alone is not the Ideal Dose for the ' 'Treatment of COVID-19', 'author': 'Schmith', 'year': '2020', 'journal-title': 'Clin. Pharmacol. Ther.'}, { 'issue': '4', 'key': '10.1016/j.intimp.2021.108004_b0145', 'doi-asserted-by': 'crossref', 'first-page': '1004', 'DOI': '10.7150/jca.26277', 'article-title': 'Tumor-associated inflammatory microenvironment in non-small cell lung ' 'cancer: correlation with FGFR1 and TLR4 expression via PI3K/Akt pathway', 'volume': '10', 'author': 'Zhang', 'year': '2019', 'journal-title': 'J Cancer.'}, { 'key': '10.1016/j.intimp.2021.108004_b0150', 'series-title': 'Therapeutic nanostructures for pulmonary drug delivery. Nanostructures ' 'for Drug Delivery', 'first-page': '619', 'author': 'Javadzadeh', 'year': '2017'}, { 'issue': '122', 'key': '10.1016/j.intimp.2021.108004_b0155', 'doi-asserted-by': 'crossref', 'first-page': '64', 'DOI': '10.1016/j.ejps.2018.06.015', 'article-title': 'Design and characterization of emulsified spray dried alginate ' 'microparticles as a carrier for the dually acting drug roflumilast', 'volume': '15', 'author': 'Mahmoud', 'year': '2018', 'journal-title': 'Eur. J. Pharm. Sci.'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.108004_b0160', 'doi-asserted-by': 'crossref', 'first-page': '79', 'DOI': '10.1016/S0928-0987(01)00208-1', 'article-title': 'Physicochemical characterization and in vitro dissolution behavior of ' 'nicardipine-cyclodextrins inclusion compounds', 'volume': '15', 'author': 'Fernandes', 'year': '2002', 'journal-title': 'Eur. J. Pharm. Sci.'}, { 'issue': '1–2', 'key': '10.1016/j.intimp.2021.108004_b0165', 'doi-asserted-by': 'crossref', 'first-page': '205', 'DOI': '10.1016/S0378-5173(98)00068-4', 'article-title': 'Formation of cyclodextrin inclusion complexes with corticosteroids: ' 'their characterization and stability', 'volume': '167', 'author': 'Vianna', 'year': '1998', 'journal-title': 'Int. J. Pharm.'}, { 'issue': '1–2', 'key': '10.1016/j.intimp.2021.108004_b0170', 'doi-asserted-by': 'crossref', 'first-page': '45', 'DOI': '10.1016/0378-5173(95)04214-8', 'article-title': 'Characterization and bioavailability of danazol-hydroxypropyl ' 'β-cyclodextrin coprecipitates', 'volume': '128', 'author': 'Badawy', 'year': '1996', 'journal-title': 'Int. J. Pharm.'}, { 'issue': '9', 'key': '10.1016/j.intimp.2021.108004_b0175', 'doi-asserted-by': 'crossref', 'first-page': '2951', 'DOI': '10.1021/acs.molpharmaceut.6b00167', 'article-title': 'Nano Spray Drying Technique as a Novel Approach To Formulate Stable ' 'Econazole Nitrate Nanosuspension Formulations for Ocular Use', 'volume': '13', 'author': 'Maged', 'year': '2016', 'journal-title': 'Mol. Pharm.'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.108004_b0180', 'doi-asserted-by': 'crossref', 'DOI': '10.4172/2380-9477.1000121', 'article-title': 'Hydroxypropyl-beta-cyclodextrin as cryoprotectant in nanoparticles ' 'prepared by nano-spray drying technique', 'volume': '5', 'author': 'Maged', 'year': '2017', 'journal-title': 'J. Pharm. Sci. Emerg. Drugs'}, { 'issue': '13', 'key': '10.1016/j.intimp.2021.108004_b0185', 'doi-asserted-by': 'crossref', 'first-page': '1086', 'DOI': '10.1016/j.addr.2011.08.003', 'article-title': 'Protein stabilization by cyclodextrins in the liquid and dried state', 'volume': '63', 'author': 'Serno', 'year': '2011', 'journal-title': 'Adv. Drug Deliv. Rev.'}, { 'issue': '12', 'key': '10.1016/j.intimp.2021.108004_b0190', 'doi-asserted-by': 'crossref', 'first-page': '2369', 'DOI': '10.1007/s11095-004-7691-5', 'article-title': 'Effects of hydrophilic cyclodextrins on aggregation of recombinant ' 'human growth hormone', 'volume': '21', 'author': 'Tavornvipas', 'year': '2004', 'journal-title': 'Pharm. Res.'}, { 'issue': '9', 'key': '10.1016/j.intimp.2021.108004_b0195', 'doi-asserted-by': 'crossref', 'first-page': '1157', 'DOI': '10.1023/A:1015847604654', 'article-title': 'Cyclodextrins as nasal absorption promoters of insulin: mechanistic ' 'evaluations', 'volume': '9', 'author': 'Shao', 'year': '1992', 'journal-title': 'Pharm. Res.'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.108004_b0200', 'doi-asserted-by': 'crossref', 'first-page': '257', 'DOI': '10.1023/A:1023013523416', 'article-title': 'Improvement in the physicochemical properties of ketoconazole through ' 'complexation with cyclodextrin derivatives', 'volume': '44', 'author': 'Taneri', 'year': '2002', 'journal-title': 'J Incl Macrocycl Chem.'}, { 'issue': '2–3', 'key': '10.1016/j.intimp.2021.108004_b0205', 'doi-asserted-by': 'crossref', 'first-page': '303', 'DOI': '10.1016/0378-5173(91)90331-H', 'article-title': 'Studies of cyclodextrin inclusion complexes. IV. The pulmonary ' 'absorption of salbutamol from a complex with ' '2-hydroxypropyl-β-cyclodextrin in rabbits', 'volume': '77', 'author': 'Marques', 'year': '1991', 'journal-title': 'Int. J. Pharm.'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.108004_b0210', 'doi-asserted-by': 'crossref', 'first-page': '20', 'DOI': '10.1208/s12249-020-01889-5', 'article-title': 'Aerosolization Performance, Antitussive Effect and Local Toxicity of ' 'Naringenin-Hydroxypropyl-beta-Cyclodextrin Inhalation Solution for ' 'Pulmonary Delivery', 'volume': '22', 'author': 'Guan', 'year': '2021', 'journal-title': 'AAPS PharmSciTech.'}, { 'issue': '3', 'key': '10.1016/j.intimp.2021.108004_b0215', 'doi-asserted-by': 'crossref', 'first-page': '403', 'DOI': '10.1080/03639045.2020.1724131', 'article-title': 'Hydroxypropyl beta cyclodextrin: a water-replacement agent or a ' 'surfactant upon spray freeze-drying of IgG with enhanced stability and ' 'aerosolization', 'volume': '46', 'author': 'Milani', 'year': '2020', 'journal-title': 'Drug Dev. Ind. Pharm.'}, { 'key': '10.1016/j.intimp.2021.108004_b0220', 'unstructured': 'D. Cataldo, B. Evrard, A. Noel, J.-M. Foldart, Inventors; Use of ' 'cyclodextrin for treatment and prevention of bronchial inflammatory ' 'diseases, 2015.'}, { 'key': '10.1016/j.intimp.2021.108004_b0225', 'unstructured': 'A. Martin, Physical pharmacy: physical chemical principles in the ' 'pharmaceutical sciences: BI Waverly. Pvt Ltd; 1993.'}, { 'issue': '9', 'key': '10.1016/j.intimp.2021.108004_b0230', 'doi-asserted-by': 'crossref', 'first-page': '2673', 'DOI': '10.1002/jps.23998', 'article-title': 'Next generation drying technologies for pharmaceutical applications', 'volume': '103', 'author': 'Walters', 'year': '2014', 'journal-title': 'J. Pharm. Sci.'}, { 'key': '10.1016/j.intimp.2021.108004_b0235', 'unstructured': 'Lubrizol CDMO. Lyophilization of Pharmaceuticals: An Overview. 2019; ' 'Available from: ' 'https://lubrizolcdmo.com/blog/lyophilization-of-pharmaceuticals-an-overview/.'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.108004_b0240', 'doi-asserted-by': 'crossref', 'first-page': '314', 'DOI': '10.1208/s12249-008-9042-z', 'article-title': 'Physicochemical properties and dissolution studies of dexamethasone ' 'acetate-beta-cyclodextrin inclusion complexes produced by different ' 'methods', 'volume': '9', 'author': 'Doile', 'year': '2008', 'journal-title': 'AAPS PharmSciTech.'}, { 'key': '10.1016/j.intimp.2021.108004_b0245', 'unstructured': 'WHO. WHO advises that ivermectin only be used to treat COVID-19 within ' 'clinical trials. 2021 [cited 2021 July]; Available from: ' 'https://www.who.int/news-room/feature-stories/detail/who-advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials.'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.108004_b0250', 'doi-asserted-by': 'crossref', 'first-page': '162', 'DOI': '10.1016/j.ejpb.2009.04.005', 'article-title': 'In vitro and in vivo evaluation of nimesulide lyophilized orally ' 'disintegrating tablets', 'volume': '73', 'author': 'Shoukri', 'year': '2009', 'journal-title': 'Eur. J. Pharm. Biopharm. : Off. J. Arbeitsgemeinschaft fur ' 'Pharmazeutische Verfahrenstechnik eV [Comparative Study Randomized ' 'Controlled Trial].'}, { 'key': '10.1016/j.intimp.2021.108004_b0255', 'doi-asserted-by': 'crossref', 'first-page': '141', 'DOI': '10.1016/j.pharmthera.2017.04.003', 'article-title': 'Inhaled efficacious dose translation from rodent to human: A ' 'retrospective analysis of clinical standards for respiratory diseases', 'volume': '178', 'author': 'Phillips', 'year': '2017', 'journal-title': 'Pharmacol. Ther.'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.108004_b0260', 'doi-asserted-by': 'crossref', 'first-page': '167', 'DOI': '10.1007/s10787-020-00748-w', 'article-title': 'MiR-200a inversely correlates with Hedgehog and TGF-beta ' 'canonical/non-canonical trajectories to orchestrate the anti-fibrotic ' 'effect of Tadalafil in a bleomycin-induced pulmonary fibrosis model', 'volume': '29', 'author': 'Mansour', 'year': '2021', 'journal-title': 'Inflammopharmacology'}, { 'key': '10.1016/j.intimp.2021.108004_b0265', 'series-title': "Bancroft's theory and practice of histological techniques E-Book", 'author': 'Suvarna', 'year': '2018'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.108004_b0270', 'doi-asserted-by': 'crossref', 'first-page': '48', 'DOI': '10.7150/ijms.8.48', 'article-title': 'Ozone therapy and hyperbaric oxygen treatment in lung injury in septic ' 'rats', 'volume': '8', 'author': 'Yamanel', 'year': '2011', 'journal-title': 'Int. J. Med. Sci.'}, { 'key': '10.1016/j.intimp.2021.108004_b0275', 'doi-asserted-by': 'crossref', 'DOI': '10.1007/s43440-020-00195-y', 'article-title': 'Ivermectin as a potential drug for treatment of COVID-19: an in-sync ' 'review with clinical and computational attributes', 'author': 'Kaur', 'year': '2021', 'journal-title': 'Pharmacol. Rep.'}, { 'issue': '329', 'key': '10.1016/j.intimp.2021.108004_b0280', 'doi-asserted-by': 'crossref', 'first-page': '758', 'DOI': '10.1016/j.jconrel.2020.10.009', 'article-title': 'Ivermectin: an award-winning drug with expected antiviral activity ' 'against COVID-19', 'volume': '10', 'author': 'Formiga', 'year': '2021', 'journal-title': 'J. Control. Release'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.108004_b0285', 'doi-asserted-by': 'crossref', 'first-page': '17073', 'DOI': '10.1038/s41598-020-74084-y', 'article-title': 'Nebulized ivermectin for COVID-19 and other respiratory diseases, a ' 'proof of concept, dose-ranging study in rats', 'volume': '10', 'author': 'Chaccour', 'year': '2020', 'journal-title': 'Sci. Rep.'}, { 'key': '10.1016/j.intimp.2021.108004_b0290', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.mehy.2020.110364', 'article-title': 'Inhaled route and anti-inflammatory action of ivermectin: Do they hold ' 'promise in fighting against COVID-19?', 'volume': '146', 'author': 'Mittal', 'year': '2021', 'journal-title': 'Med. Hypotheses'}, { 'key': '10.1016/j.intimp.2021.108004_b0295', 'unstructured': 'WHO. Proposal to waive in vivo bioequivalence requirements for the who ' 'model list of essential medicines immediate release, solid oral dosage ' 'forms. Working document QAS/04109/Rev1. 2005.'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.108004_b0300', 'doi-asserted-by': 'crossref', 'first-page': '349', 'DOI': '10.1007/s10847-006-9261-4', 'article-title': 'Complexation of hydrophobic drugs with hydroxypropyl-β-cyclodextrin by ' 'lyophilization using a tertiary butyl alcohol system', 'volume': '57', 'author': 'Wang', 'year': '2007', 'journal-title': 'J. Incl. Phenom. Macrocycl. Chem.'}, { 'issue': '2', 'key': '10.1016/j.intimp.2021.108004_b0305', 'doi-asserted-by': 'crossref', 'first-page': '335', 'DOI': '10.1517/17425247.2.1.335', 'article-title': 'Cyclodextrins in drug delivery', 'volume': '2', 'author': 'Loftsson', 'year': '2005', 'journal-title': 'Expert Opinion on Drug Delivery.'}, { 'issue': '5', 'key': '10.1016/j.intimp.2021.108004_b0310', 'doi-asserted-by': 'crossref', 'DOI': '10.3390/molecules23051161', 'article-title': 'Solubility of Cyclodextrins and Drug/Cyclodextrin Complexes', 'volume': '23', 'author': 'Saokham', 'year': '2018', 'journal-title': 'Molecules'}, { 'issue': '7', 'key': '10.1016/j.intimp.2021.108004_b0315', 'doi-asserted-by': 'crossref', 'first-page': '645', 'DOI': '10.1016/j.addr.2007.05.012', 'article-title': 'Cyclodextrins as pharmaceutical solubilizers', 'volume': '59', 'author': 'Brewster', 'year': '2007', 'journal-title': 'Adv. Drug Deliv. Rev.'}, { 'issue': '11', 'key': '10.1016/j.intimp.2021.108004_b0320', 'doi-asserted-by': 'crossref', 'first-page': '1142', 'DOI': '10.1021/js960075u', 'article-title': 'Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery', 'volume': '85', 'author': 'Rajewski', 'year': '1996', 'journal-title': 'J. Pharm. Sci.'}, { 'issue': '3', 'key': '10.1016/j.intimp.2021.108004_b0325', 'doi-asserted-by': 'crossref', 'first-page': '704', 'DOI': '10.1208/s12249-014-0257-x', 'article-title': 'Effects of the preparation method on the formation of true nimodipine ' 'SBE-β-CD/HP-β-CD inclusion complexes and their dissolution rates ' 'enhancement', 'volume': '16', 'author': 'Semcheddine', 'year': '2015', 'journal-title': 'AAPS PharmSciTech.'}, { 'key': '10.1016/j.intimp.2021.108004_b0330', 'doi-asserted-by': 'crossref', 'first-page': '120', 'DOI': '10.1016/j.jconrel.2019.02.019', 'article-title': 'Continuous alternative to freeze drying: Manufacturing of ' 'cyclodextrin-based reconstitution powder from aqueous solution using ' 'scaled-up electrospinning', 'volume': '298', 'author': 'Vass', 'year': '2019', 'journal-title': 'J. Control. Release'}, { 'issue': '2', 'key': '10.1016/j.intimp.2021.108004_b0335', 'doi-asserted-by': 'crossref', 'first-page': '365', 'DOI': '10.1016/j.jpba.2003.12.005', 'article-title': 'Effects of alpha- and beta-cyclodextrin complexation on the ' 'physico-chemical properties and antioxidant activity of some ' '3-hydroxyflavones', 'volume': '35', 'author': 'Calabro', 'year': '2004', 'journal-title': 'J. Pharm. Biomed. Anal. [Comparative Study].'}, { 'issue': '1–2', 'key': '10.1016/j.intimp.2021.108004_b0340', 'doi-asserted-by': 'crossref', 'first-page': '129', 'DOI': '10.1016/j.ijpharm.2005.11.024', 'article-title': 'Formulation and biological evaluation of ' 'glimepiride-cyclodextrin-polymer systems', 'volume': '309', 'author': 'Ammar', 'year': '2006', 'journal-title': 'Int. J. Pharm.'}, { 'key': '10.1016/j.intimp.2021.108004_b0345', 'doi-asserted-by': 'crossref', 'first-page': '3291', 'DOI': '10.2147/IJN.S78814', 'article-title': 'Hydroxypropyl-beta-cyclodextrin functionalized calcium carbonate ' 'microparticles as a potential carrier for enhancing oral delivery of ' 'water-insoluble drugs', 'volume': '10', 'author': 'Zhang', 'year': '2015', 'journal-title': 'Int. J. Nanomed.'}, { 'issue': '8', 'key': '10.1016/j.intimp.2021.108004_b0350', 'doi-asserted-by': 'crossref', 'first-page': '2128', 'DOI': '10.1021/cm9601188', 'article-title': 'Vitrification and crystallization of organic liquids confined to ' 'nanoscale pores', 'volume': '8', 'author': 'Jackson', 'year': '1996', 'journal-title': 'Chem. Mater.'}, { 'issue': '11', 'key': '10.1016/j.intimp.2021.108004_b0355', 'doi-asserted-by': 'crossref', 'first-page': '1020', 'DOI': '10.1136/thoraxjnl-2015-208032', 'article-title': 'Alveolar macrophage-derived microvesicles mediate acute lung injury', 'volume': '71', 'author': 'Soni', 'year': '2016', 'journal-title': 'Thorax'}, { 'issue': '2', 'key': '10.1016/j.intimp.2021.108004_b0360', 'doi-asserted-by': 'crossref', 'first-page': '164', 'DOI': '10.5507/bp.2017.029', 'article-title': 'Inflammatory, anti-inflammatory and regulatory cytokines in relatively ' 'healthy lung tissue as an essential part of the local immune system', 'volume': '161', 'author': 'Vitenberga', 'year': '2017', 'journal-title': 'Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.'}, { 'issue': '2', 'key': '10.1016/j.intimp.2021.108004_b0365', 'doi-asserted-by': 'crossref', 'first-page': '287', 'DOI': '10.1093/toxsci/kfy309', 'article-title': 'Role of Macrophages in Acute Lung Injury and Chronic Fibrosis Induced ' 'by Pulmonary Toxicants', 'volume': '168', 'author': 'Laskin', 'year': '2019', 'journal-title': 'Toxicol. Sci.'}, { 'key': '10.1016/j.intimp.2021.108004_b0370', 'doi-asserted-by': 'crossref', 'DOI': '10.1155/2015/816460', 'article-title': 'Understanding the Mysterious M2 Macrophage through Activation Markers ' 'and Effector Mechanisms', 'volume': '2015', 'author': 'Roszer', 'year': '2015', 'journal-title': 'Mediators Inflamm.'}, { 'issue': '6', 'key': '10.1016/j.intimp.2021.108004_b0375', 'doi-asserted-by': 'crossref', 'first-page': '687', 'DOI': '10.1084/jem.20020903', 'article-title': 'Regulation and function of the interleukin 13 receptor alpha 2 during a ' 'T helper cell type 2-dominant immune response', 'volume': '197', 'author': 'Chiaramonte', 'year': '2003', 'journal-title': 'J. Exp. Med.'}, { 'issue': '5', 'key': '10.1016/j.intimp.2021.108004_b0380', 'doi-asserted-by': 'crossref', 'first-page': '2684', 'DOI': '10.4049/jimmunol.171.5.2684', 'article-title': 'Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- ' 'and IL-13-responsive cells', 'volume': '171', 'author': 'Jakubzick', 'year': '2003', 'journal-title': 'J. Immunol.'}, { 'key': '10.1016/j.intimp.2021.108004_b0385', 'article-title': 'Circulating Procollagen type III N-terminal peptide (P3NP) and Physical ' 'Function in Adults from The Long Life Family Study', 'volume': '14', 'author': 'Santanasto', 'year': '2020', 'journal-title': 'J. Gerontol. A Biol. Sci. Med. Sci.'}, { 'issue': '5', 'key': '10.1016/j.intimp.2021.108004_b0390', 'doi-asserted-by': 'crossref', 'first-page': '1783', 'DOI': '10.1164/ajrccm.162.5.2001061', 'article-title': 'Fibroproliferation occurs early in the acute respiratory distress ' 'syndrome and impacts on outcome', 'volume': '162', 'author': 'Marshall', 'year': '2000', 'journal-title': 'Am. J. Respir. Crit. Care Med.'}, { 'issue': '18', 'key': '10.1016/j.intimp.2021.108004_b0395', 'doi-asserted-by': 'crossref', 'DOI': '10.1097/MD.0000000000006617', 'article-title': 'Association of serum levels of laminin, type IV collagen, procollagen ' 'III N-terminal peptide, and hyaluronic acid with the progression of ' 'interstitial lung disease', 'volume': '96', 'author': 'Su', 'year': '2017', 'journal-title': 'Medicine (Baltimore).'}, { 'issue': '2', 'key': '10.1016/j.intimp.2021.108004_b0400', 'doi-asserted-by': 'crossref', 'first-page': '126', 'DOI': '10.1136/thx.44.2.126', 'article-title': 'Hyaluronan and type III procollagen peptide concentrations in ' 'bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis', 'volume': '44', 'author': 'Bjermer', 'year': '1989', 'journal-title': 'Thorax'}, { 'issue': '2', 'key': '10.1016/j.intimp.2021.108004_b0405', 'doi-asserted-by': 'crossref', 'first-page': '389', 'DOI': '10.1164/ajrccm.163.2.2004168', 'article-title': 'Deficiencies in lung surfactant proteins A and D are associated with ' 'lung infection in very premature neonatal baboons', 'volume': '163', 'author': 'Awasthi', 'year': '2001', 'journal-title': 'Am. J. Respir. Crit. Care Med.'}, { 'issue': '3', 'key': '10.1016/j.intimp.2021.108004_b0410', 'doi-asserted-by': 'crossref', 'first-page': '181', 'DOI': '10.1034/j.1399-0004.2000.580305.x', 'article-title': 'Polymorphisms of human SP-A, SP-B, and SP-D genes: association of SP-B ' 'Thr131Ile with ARDS', 'volume': '58', 'author': 'Lin', 'year': '2000', 'journal-title': 'Clin. Genet.'}, { 'issue': '6', 'key': '10.1016/j.intimp.2021.108004_b0415', 'doi-asserted-by': 'crossref', 'first-page': '668', 'DOI': '10.1165/ajrcmb.25.6.f221', 'article-title': 'Surfactant protein A (SP-A)-mediated bacterial clearance: SP-A and ' 'cystic fibrosis', 'volume': '25', 'author': 'Korfhagen', 'year': '2001', 'journal-title': 'Am. J. Respir. Cell Mol. Biol.'}, { 'issue': '3', 'key': '10.1016/j.intimp.2021.108004_b0420', 'doi-asserted-by': 'crossref', 'first-page': '723', 'DOI': '10.1164/ajrccm/147.3.723', 'article-title': 'Elevated levels of lung surfactant protein A in sera from patients with ' 'idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis', 'volume': '147', 'author': 'Kuroki', 'year': '1993', 'journal-title': 'Am. Rev. Respir. Dis.'}, { 'issue': '3', 'key': '10.1016/j.intimp.2021.108004_b0425', 'doi-asserted-by': 'crossref', 'first-page': 'H969', 'DOI': '10.1152/ajpheart.00400.2008', 'article-title': 'Leukocyte-endothelial cell interactions are linked to vascular ' 'permeability via ICAM-1-mediated signaling', 'volume': '295', 'author': 'Sumagin', 'year': '2008', 'journal-title': 'Am. J. Physiol. Heart Circ. Physiol.'}, { 'issue': '4', 'key': '10.1016/j.intimp.2021.108004_b0430', 'doi-asserted-by': 'crossref', 'first-page': '652', 'DOI': '10.1097/BCR.0b013e3181e4c58c', 'article-title': 'Decreased pulmonary inflammation after ethanol exposure and burn injury ' 'in intercellular adhesion molecule-1 knockout mice', 'volume': '31', 'author': 'Bird', 'year': '2010', 'journal-title': 'J. Burn Care Res.'}, { 'issue': '7', 'key': '10.1016/j.intimp.2021.108004_b0435', 'doi-asserted-by': 'crossref', 'first-page': '815', 'DOI': '10.1183/09031936.93.05070815', 'article-title': 'Intercellular adhesion molecule-1 (ICAM-1) and endothelial leucocyte ' 'adhesion molecule-1 (ELAM-1) expression in the bronchial mucosa of ' 'normal and asthmatic subjects', 'volume': '5', 'author': 'Montefort', 'year': '1992', 'journal-title': 'Eur. Respir. J.'}, { 'issue': '2–3', 'key': '10.1016/j.intimp.2021.108004_b0440', 'doi-asserted-by': 'crossref', 'first-page': '171', 'DOI': '10.1016/S0167-5273(02)00138-9', 'article-title': 'C/T polymorphism of the intercellular adhesion molecule-1 gene (exon 6, ' 'codon 469). A risk factor for coronary heart disease and myocardial ' 'infarction', 'volume': '84', 'author': 'Jiang', 'year': '2002', 'journal-title': 'Int. J. Cardiol.'}, { 'issue': '10', 'key': '10.1016/j.intimp.2021.108004_b0445', 'doi-asserted-by': 'crossref', 'first-page': '733', 'DOI': '10.1093/jnci/94.10.733', 'article-title': 'Effects of intercellular adhesion molecule 1 (ICAM-1) null mutation on ' 'radiation-induced pulmonary fibrosis and respiratory insufficiency in ' 'mice', 'volume': '94', 'author': 'Hallahan', 'year': '2002', 'journal-title': 'J. Natl Cancer Inst.'}, { 'issue': '21–22', 'key': '10.1016/j.intimp.2021.108004_b0450', 'doi-asserted-by': 'crossref', 'first-page': '1570', 'DOI': '10.1016/j.cca.2010.07.006', 'article-title': 'MCP-1: chemoattractant with a role beyond immunity: a review', 'volume': '411', 'author': 'Yadav', 'year': '2010', 'journal-title': 'Clin. Chim. Acta'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.108004_b0455', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1016/j.cyto.2012.06.018', 'article-title': 'Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes', 'volume': '60', 'author': 'Panee', 'year': '2012', 'journal-title': 'Cytokine'}, { 'issue': '1', 'key': '10.1016/j.intimp.2021.108004_b0460', 'doi-asserted-by': 'crossref', 'first-page': '63', 'DOI': '10.1016/j.humimm.2015.10.005', 'article-title': 'TLR stimulation of human neutrophils lead to increased release of ' 'MCP-1, MIP-1alpha, IL-1beta, IL-8 and TNF during tuberculosis', 'volume': '77', 'author': 'Hilda', 'year': '2016', 'journal-title': 'Hum. Immunol.'}, { 'issue': '4', 'key': '10.1016/j.intimp.2021.108004_b0465', 'doi-asserted-by': 'crossref', 'first-page': '810', 'DOI': '10.1002/ejp.1169', 'article-title': 'Blocking of cytokines signalling attenuates evoked and spontaneous ' 'neuropathic pain behaviours in the paclitaxel rat model of ' 'chemotherapy-induced neuropathy', 'volume': '22', 'author': 'Al-Mazidi', 'year': '2018', 'journal-title': 'Eur. J. Pain'}, { 'issue': '2', 'key': '10.1016/j.intimp.2021.108004_b0470', 'doi-asserted-by': 'crossref', 'first-page': '213', 'DOI': '10.1007/s13555-017-0176-3', 'article-title': 'Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression ' 'of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in ' 'Reconstructed and Ex Vivo Skin Models', 'volume': '7', 'author': 'Thibaut de Menonville', 'year': '2017', 'journal-title': 'Dermatol Ther (Heidelb)'}, { 'issue': '5', 'key': '10.1016/j.intimp.2021.108004_b0475', 'doi-asserted-by': 'crossref', 'first-page': '438', 'DOI': '10.1016/j.micinf.2011.12.002', 'article-title': 'Chemokines and cytokines in patients with an occult Onchocerca volvulus ' 'infection', 'volume': '14', 'author': 'Lechner', 'year': '2012', 'journal-title': 'Microbes Infect.'}], 'container-title': 'International Immunopharmacology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1567576921006408?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1567576921006408?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2023, 4, 15]], 'date-time': '2023-04-15T09:30:09Z', 'timestamp': 1681551009000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1567576921006408'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 10]]}, 'references-count': 95, 'alternative-id': ['S1567576921006408'], 'URL': 'http://dx.doi.org/10.1016/j.intimp.2021.108004', 'relation': {}, 'ISSN': ['1567-5769'], 'subject': [], 'container-title-short': 'International Immunopharmacology', 'published': {'date-parts': [[2021, 10]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Safety of inhaled ivermectin as a repurposed direct drug for treatment of ' 'COVID-19: A preclinical tolerance study', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'International Immunopharmacology', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.intimp.2021.108004', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2021 Elsevier B.V. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '108004'}